fluorine-18 alfa peptide

Fluorine-18 alfa peptide (also known as 18F-Alfatide) is a radiopharmaceutical diagnostic imaging agent developed for Positron Emission Tomography (PET). It consists of a dimeric cyclic RGD (Arg-Gly-Asp) peptide (specifically PRGD2) conjugated to a NOTA chelator and labeled with a fluorine-18 aluminum fluoride ([18F]AlF) complex. The agent specifically targets integrin αvβ3, a cell surface receptor that is significantly upregulated on activated endothelial cells during tumor-induced angiogenesis and on various tumor cell types, including lung cancer and glioblastoma. By binding to integrin αvβ3, fluorine-18 alfa peptide allows for the non-invasive visualization and quantification of angiogenesis and tumor receptor expression. The development in China has been led by Jiangsu Simcere Pharmaceutical and Taizhou Qirui Pharmaceutical Technology, with clinical investigations focusing on its safety, biodistribution, and efficacy in imaging malignant neoplasms.

Other names

fluorine-18 alfa peptide injectionfluorine18 alfa peptide injectionfluorine 18 alfa peptide injection[18F]AlF-NOTA-PRGD2Fluorine-18 AlF-NOTA-PRGD2Fluorine18 AlF-NOTA-PRGD2Fluorine 18 AlF-NOTA-PRGD218F-AlF-NOTA-PRGD2